MBX Biosciences has appointed Andreas Moraitis, M.D., as Senior Vice President of Clinical Development, bringing extensive endocrinology expertise to advance the company's lead product candidate canvuparatide for hypoparathyroidism treatment. The clinical-stage biopharmaceutical company announced the appointment as it continues developing novel precision peptide therapies for endocrine and metabolic disorders.
"Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "Andreas' deep expertise in endocrinology and proven track record of leading clinical development programs, from Investigational New Drug (IND) application to New Drug Application (NDA), make him an exceptional addition to our leadership team as we advance canvuparatide and our growing pipeline of obesity and rare disease product candidates."
Clinical Development Expertise
Dr. Moraitis is a board-certified endocrinologist with extensive experience leading clinical development programs for endocrine and metabolic indications. Prior to joining MBX, he spent over a decade at Corcept Therapeutics, where he oversaw endocrine clinical development. During his tenure at Corcept, he led the design and execution of clinical programs in rare endocrine diseases, supported the initial NDA filing of relacorilant for hypercortisolism, and collaborated closely with regulatory authorities throughout the clinical development process.
His academic background includes serving as Clinical Assistant Professor in the Endocrine Oncology Program at the University of Michigan and as volunteer clinical faculty at the VA Medical Center in Orlando. Dr. Moraitis completed a fellowship in Adult and Reproductive Endocrinology at the National Institutes of Health and holds an M.D. from the National and Kapodistrian University of Athens. He is certified by the American Board of Internal Medicine in internal medicine and endocrinology, metabolism, and diabetes.
"I have dedicated my career to developing new approaches for people living with complex endocrine conditions," said Dr. Moraitis. "I am delighted to join MBX and look forward to working with this talented and experienced team to advance canvuparatide and help bring new potential treatments to patients whose needs are not adequately managed by existing treatments."
Pipeline Development
MBX Biosciences is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The company's pipeline includes canvuparatide (MBX 2109), currently in Phase 2 development for the treatment of chronic hypoparathyroidism.
Additional pipeline candidates include imapextide (MBX 1416), in Phase 1 development for the treatment of post-bariatric hypoglycemia, and an obesity portfolio that includes MBX 4291, with an IND currently under FDA review, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity.
Platform Technology
The company's drug development efforts are based on its proprietary PEP™ platform for the discovery and development of novel precision peptide therapies. MBX Biosciences focuses specifically on the treatment of endocrine and metabolic disorders, targeting conditions with significant unmet medical needs and large potential market opportunities.
